*PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer DOI: http://dx.doi.org/10.5772/intechopen.106659*

[21, 44, 47, 48, 51, 54, 55]. Fatigue adverse events are largely mild to moderate (grade 1–2) and tend to occur early during initial phase of the PARPi therapy [56, 57].

It is important to note that patients may have baseline cancer-related fatigue as it affects 65% of patients with cancer [58]. Fatigue from chemotherapy can impact patient's desire to start maintenance therapy. Prior to the initiation of PARPi, HCPs shall assess and screen patient for baseline fatigue and counsel patient on the risks of fatigue as an adverse event of PARPi for shared treatment decision-making [59].

Fatigue can be scored and routinely assessed as a self-report subjective score using a 10-point numerical rating scale. Pharmacological treatment of psychostimulants may be considered for a short period after thorough evaluation. Physical exercises such as walking, aerobic, and resistance exercises are recommended in non-cachectic patients. Other modalities to manage fatigue include psychoeducation to help patients by promoting self-management, adaptation, and adjustment to their existing situation and environment, and cognitive behavioral therapy. Practicing mindfulness and yoga could be an option to improve fatigue symptoms [58, 59].
